Investigational Site Number : 056001

Leuven 3000

0 studies enrolling now · 14 studies all time

What they study most

Acid Maltase Deficiency, Asthma, Diffuse Large B-cell Lymphoma, Glycogen Storage Disease Type II (GSD II), Glycogen Storage Disease Type II Pompe Disease, Hematopoietic Neoplasm, Hypercholesterolaemia, Lymphoma, Multiple Sclerosis, Neoplasm Malignant, Ovarian Cancer Recurrent, Pompe Disease

Studies at this site

• Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis — Completed
• Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis — Completed
• Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency — Completed
• A Long-Term Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency — Completed
• Avalglucosidase Alfa Extension Study — Completed
• Safety and Efficacy Evaluation of Repeat neoGAA Dosing in Late Onset Pompe Disease Patients. — Completed
• Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen — Completed
• Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE) — Completed
• Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma — Completed
• Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin) — Completed
• SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients — Completed
• Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM — Completed
• A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia — Completed
• Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel — Completed